Adam S. Kibel, MD, argues that aggressive curative therapy is the best practice for the management of high-risk prostate cancer. He observes that local therapies like surgery, along with combination therapies like external beam radiation therapy plus brachytherapy and androgen deprivation therapy, have shown themselves to be effective for improving overall survival.
Read More
Alan W. Shindel, MD, MAS, discusses the current treatment of erectile dysfunction (ED) with PDE5 inhibitors, as well as the limitations of the currently available drugs for ED patients. He also reviews a number of potential targets for novel ED treatments, including nitric oxide, soluble guanylate cyclase, the RhoA/Rho Kinase/ROCK pathway, and the Sonic Hedgehog protein.
Read More
Adam S. Kibel, MD, argues that the preponderance of evidence shows surgery outperforming radiation therapy when treating prostate cancer patients. He discusses the randomized data still needed to accurately compare these two treatments and multiple case series and a meta-analysis that favor surgery in terms of overall survival, as well as the benefit of surgery in terms of providing an opportunity for optimal staging and subsequent treatment.
Read More
Arthur L. Burnett II, MD, MBA, FACS, presents the rationale for invoking therapeutic strategies for enhancing erectile function recovery following radical prostatectomy. He assesses possible therapeutic strategies that target the cavernous nerve in order to restoring erectile function and identifies the requirements and future possibilities for penile rehabilitation success.
Read More
Fernando J. Kim, MD, MBA, FACS, reviews the historical events contributing to the emergence of patient safety as a healthcare discipline. He describes efforts in the urologic field, specifically from the American Urological Association (AUA), to advance the culture of patient safety.
Read More